Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Inclusion Criteria: * Pediatric patients aged 4-18 years * Persistent proteinuria \> 500 mg/day despite standard therapy. * Stable renal function (eGFR ≥ 30 mL/min/1.73 m²). * Ability to comply with follow-up visits and study procedures. * Written informed consent obtained from parents or legal guardians, and assent from the patient when appropriate. Exclusion Criteria: * Known hypersensitivity or contraindication to dapagliflozin or other SGLT2 inhibitors. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or end-stage renal disease requiring dialysis. * Active urinary tract infection, severe dehydration, or hypotension. * Participation in another clinical trial within the last 30 days. * Any comorbid condition or medical history that, in the investigator's opinion, would interfere with study participation or interpretation of results.